Published in Cancer Lett on April 02, 2013
IL4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res (2014) 1.04
Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. Ann Surg Oncol (2015) 0.96
MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of β-catenin signaling. Oncotarget (2016) 0.90
RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget (2015) 0.83
Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp Mol Med (2017) 0.79
Lessons from immunology: IL4R directly promotes mammary tumor metastasis. Oncoimmunology (2014) 0.77
Commentary: IL-4 and IL-13 receptors and signaling. Cytokine (2015) 0.77
Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis). Int J Mol Med (2015) 0.76
MicroRNA-126 inhibits the migration and invasion of endometrial cancer cells by targeting insulin receptor substrate 1. Oncol Lett (2015) 0.76
Lack of association between insulin receptor substrate2 rs1805097 polymorphism and the risk of colorectal and breast cancer: a meta-analysis. PLoS One (2014) 0.75
Increased expression of IRS-1 is associated with lymph node metastasis in nasopharyngeal carcinoma. Int J Clin Exp Pathol (2014) 0.75
Polymorphisms of insulin receptor substrate 2 are putative biomarkers for pediatric medulloblastoma: considering the genetic susceptibility and pathological diagnoses. Nagoya J Med Sci (2017) 0.75
miR-628 Promotes Burn-Induced Skeletal Muscle Atrophy via Targeting IRS1. Int J Biol Sci (2016) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Insulin signalling and the regulation of glucose and lipid metabolism. Nature (2001) 16.41
The Th1/Th2 paradigm. Immunol Today (1997) 3.96
Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie (2005) 3.20
The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem (1998) 3.00
Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle (2007) 2.48
Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents (2005) 2.10
Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol (1997) 2.02
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ (2008) 1.76
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res (1976) 1.70
Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol (2001) 1.68
Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol (2004) 1.55
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res (1997) 1.54
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene (2001) 1.51
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer (2006) 1.49
Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat Cell Biol (2010) 1.47
Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem (1999) 1.41
Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res (2006) 1.37
Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol (2011) 1.36
Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal (2009) 1.35
Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res (2009) 1.31
Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem (1998) 1.29
Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med (1978) 1.28
Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem (2000) 1.24
IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine (2008) 1.23
The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res (2008) 1.23
Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer (2000) 1.22
Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle (2007) 1.22
Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol (1994) 1.19
Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol (2006) 1.19
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol (2004) 1.18
Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res (1997) 1.17
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry A (2011) 1.12
Promising molecular targeted therapies in breast cancer. Indian J Pharmacol (2011) 1.11
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie (1984) 1.10
Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res (2009) 1.09
Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res (2009) 1.08
Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat (2004) 1.05
Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. Mol Endocrinol (1999) 1.04
Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res (1995) 1.02
Perspective: The insulin signaling system--a common link in the pathogenesis of type 2 diabetes. Endocrinology (2000) 1.01
Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol (2009) 1.00
Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene (2003) 0.98
Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer (1999) 0.98
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol (2012) 0.96
Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J Clin Pathol (2005) 0.94
Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol (2006) 0.93
Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res (2012) 0.89
Regulation of gene expression, growth, and cell survival by IL-4: contribution of multiple signaling pathways. Cell Res (1998) 0.88
Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. Cancer (1980) 0.86
Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis. Mol Pharmacol (1995) 0.84
Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs (2007) 0.84
Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer. Breast Cancer Res Treat (2011) 0.77
Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death. Exp Cell Res (2012) 0.77
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell (2008) 3.72
Interleukin-4 and interleukin-13 signaling connections maps. Science (2003) 2.69
Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci U S A (2003) 2.59
Cell migration and invasion assays. Methods (2005) 2.32
Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. J Immunol (2008) 2.06
Isolation of a highly clonogenic and multipotential subfraction of adult stem cells from bone marrow stroma. Stem Cells (2004) 1.72
N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer Res (2006) 1.71
Community analysis of chronic wound bacteria using 16S rRNA gene-based pyrosequencing: impact of diabetes and antibiotics on chronic wound microbiota. PLoS One (2009) 1.68
Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res (2004) 1.64
The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia (2005) 1.60
The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol (2008) 1.57
Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J Immunol (2006) 1.56
MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer (2011) 1.55
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci (2003) 1.52
Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat Cell Biol (2010) 1.47
EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol (2005) 1.41
Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci Signal (2008) 1.37
STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One (2012) 1.33
CD133 identifies a human bone marrow stem/progenitor cell sub-population with a repertoire of secreted factors that protect against stroke. Mol Ther (2009) 1.27
IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: contribution of E-cadherin. J Leukoc Biol (2007) 1.27
Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol (2010) 1.23
The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res (2008) 1.23
Adoptive transfer of IL-4Rα+ macrophages is sufficient to enhance eosinophilic inflammation in a mouse model of allergic lung inflammation. BMC Immunol (2012) 1.21
Regulation of inflammation by interleukin-4: a review of "alternatives". J Leukoc Biol (2012) 1.20
Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer (2007) 1.15
T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity (2013) 1.14
Regulation of the dephosphorylation of Stat6. Participation of Tyr-713 in the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem (2002) 1.13
Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect Immun (2011) 1.13
Regulation of glioma cell migration by serine-phosphorylated P311. Neoplasia (2005) 1.11
Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol Cancer Res (2003) 1.10
Macrophages as IL-25/IL-33-responsive cells play an important role in the induction of type 2 immunity. PLoS One (2013) 1.09
Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells. Mol Cancer Res (2012) 1.08
Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res (2009) 1.08
Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer. Lung Cancer (2011) 1.08
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol (2012) 1.07
Evidence of unique genotypes of beak and feather disease virus in southern Africa. J Virol (2004) 1.06
TWEAK and Fn14: new molecular targets for cancer therapy? Cancer Lett (2006) 1.06
Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol (2002) 1.06
Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression. Front Oncol (2013) 1.05
Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn (2006) 1.03
TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling. Mol Cancer Res (2010) 1.03
The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. Mol Cancer Res (2013) 0.99
The Pyk2 FERM domain as a target to inhibit glioma migration. Mol Cancer Ther (2009) 0.98
The small GTPase RhoG mediates glioblastoma cell invasion. Mol Cancer (2012) 0.98
Critical role of the FERM domain in Pyk2 stimulated glioma cell migration. Biochem Biophys Res Commun (2006) 0.98
Transcriptional control of rapid recall by memory CD4 T cells. J Immunol (2011) 0.98
Role of TWEAK and Fn14 in tumor biology. Front Biosci (2007) 0.96
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol (2012) 0.96
NF-κB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-κB pathways. J Immunol (2011) 0.95
STAT6 expression in multiple cell types mediates the cooperative development of allergic airway disease. J Immunol (2011) 0.94
Increased numbers of committed myeloid progenitors but not primitive hematopoietic stem/progenitors in mice lacking STAT6 expression. J Leukoc Biol (2004) 0.94
Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells. PLoS One (2013) 0.93
The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production. Brain Behav Immun (2004) 0.93
Interleukin-13 (IL-13) pathway. Sci STKE (2005) 0.92
Induction of uteroglobin-related protein 2 (Ugrp2) gene expression by the Th2 cytokines IL-4 and IL-13. J Immunol (2005) 0.92
TLR2 signaling and Th2 responses drive Tannerella forsythia-induced periodontal bone loss. J Immunol (2011) 0.91
Expression of neuroimmune semaphorins 4A and 4D and their receptors in the lung is enhanced by allergen and vascular endothelial growth factor. BMC Immunol (2011) 0.90
Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts. J Neurooncol (2008) 0.90
Transfer of in vivo primed transgenic T cells supports allergic lung inflammation and FIZZ1 and Ym1 production in an IL-4Rα and STAT6 dependent manner. BMC Immunol (2011) 0.90
IL-4 engagement of the type I IL-4 receptor complex enhances mouse eosinophil migration to eotaxin-1 in vitro. PLoS One (2012) 0.90
Gastroduodenal intussusception due to gastrointestinal stromal tumor (GIST) treated by laparoscopic billroth II distal gastrectomy. Surg Laparosc Endosc Percutan Tech (2006) 0.90
Alternatively spliced variants of interleukin-4 promote inflammation differentially. J Leukoc Biol (2011) 0.89
Lung vascular endothelial growth factor expression induces local myeloid dendritic cell activation. Clin Immunol (2009) 0.89
miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2. PLoS One (2012) 0.89
IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway. Cell Res (2007) 0.88
Contribution of alternatively activated macrophages to allergic lung inflammation: a tale of mice and men. J Innate Immun (2012) 0.87
An atopy-associated polymorphism in the ectodomain of the IL-4R(alpha) chain (V50) regulates the persistence of STAT6 phosphorylation. J Immunol (2009) 0.87
Dissociation of endotoxin tolerance and differentiation of alternatively activated macrophages. J Immunol (2013) 0.86
Abnormal Th1 cell differentiation and IFN-gamma production in T lymphocytes from motheaten viable mice mutant for Src homology 2 domain-containing protein tyrosine phosphatase-1. J Immunol (2005) 0.86
Splice isoforms of human interleukin-4 are functionally active in mice in vivo. Immunology (2011) 0.86
STAT6 controls the number of regulatory T cells in vivo, thereby regulating allergic lung inflammation. J Immunol (2013) 0.85
TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance. Mol Cancer Res (2013) 0.84
New programming of IL-4 receptor signal transduction in activated T cells: Stat6 induction and Th2 differentiation mediated by IL-4Ralpha lacking cytoplasmic tyrosines. J Immunol (2003) 0.84
Chronic morphine treatment promotes specific Th2 cytokine production by murine T cells in vitro via a Fas/Fas ligand-dependent mechanism. J Immunol (2005) 0.84
Overexpression of insulin receptor substrate-1, but not insulin receptor substrate-2, protects a T cell hybridoma from activation-induced cell death. J Immunol (2002) 0.81
Identification of a functional peroxisome proliferator activated receptor response element in the 3' untranslated region of the human bcl-2 gene. Int J Oncol (2004) 0.81
Cytokines in chronic respiratory diseases. F1000 Biol Rep (2013) 0.81
FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis (2014) 0.81
Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res (2014) 0.80
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. Oncogene (2002) 0.80
Transgenic expression of insulin receptor substrate 2 in murine B cells alters the cell density-dependence of IgE production in vitro and enhances IgE production in vivo. J Immunol (2004) 0.80
Interleukin-4 (IL-4) pathway. Sci STKE (2005) 0.80
Phosphatidylcholine-specific phospholipase C activity is necessary for the activation of STAT6. J Immunol (2003) 0.80
Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. J Biol Chem (2013) 0.79
The extracellular and transmembrane domains of the γC and interleukin (IL)-13 receptor α1 chains, not their cytoplasmic domains, dictate the nature of signaling responses to IL-4 and IL-13. J Biol Chem (2012) 0.79
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation. Carcinogenesis (2013) 0.78
A Novel Interaction between Pyk2 and MAP4K4 Is Integrated with Glioma Cell Migration. J Signal Transduct (2013) 0.78
Pathway targets to explore in the treatment of small cell and large cell lung cancers. J Thorac Oncol (2009) 0.77
Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death. Exp Cell Res (2012) 0.77
Pathway targets to explore in the treatment of non-small cell lung cancer. J Thorac Oncol (2008) 0.76
Absence of the common gamma chain (γ(c)), a critical component of the Type I IL-4 receptor, increases the severity of allergic lung inflammation. PLoS One (2013) 0.75
Laparoscopic management of gastric outlet obstruction. ANZ J Surg (2009) 0.75
An integrated approach to identifying clinically relevant targets in pediatric gliomas. CNS Oncol (2013) 0.75